Stoke Therapeutics Stock Market Value
| STOK Stock | USD 31.91 0.02 0.06% |
| Symbol | Stoke |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 1.172 | Return On Assets | Return On Equity |
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Stoke Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Stoke Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Stoke Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Stoke Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Stoke Therapeutics or generate 0.0% return on investment in Stoke Therapeutics over 90 days. Stoke Therapeutics is related to or competes with Intellia Therapeutics, Upstream Bio, Ardelyx, Spyre Therapeutics, Wave Life, Zymeworks Common, and Pharvaris. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines t... More
Stoke Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Stoke Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Stoke Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.45 | |||
| Information Ratio | 0.1316 | |||
| Maximum Drawdown | 22.69 | |||
| Value At Risk | (5.30) | |||
| Potential Upside | 8.2 |
Stoke Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Stoke Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Stoke Therapeutics' standard deviation. In reality, there are many statistical measures that can use Stoke Therapeutics historical prices to predict the future Stoke Therapeutics' volatility.| Risk Adjusted Performance | 0.1276 | |||
| Jensen Alpha | 0.5532 | |||
| Total Risk Alpha | 0.3021 | |||
| Sortino Ratio | 0.1614 | |||
| Treynor Ratio | 0.5871 |
Stoke Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1276 | |||
| Market Risk Adjusted Performance | 0.5971 | |||
| Mean Deviation | 3.16 | |||
| Semi Deviation | 3.05 | |||
| Downside Deviation | 3.45 | |||
| Coefficient Of Variation | 675.21 | |||
| Standard Deviation | 4.23 | |||
| Variance | 17.87 | |||
| Information Ratio | 0.1316 | |||
| Jensen Alpha | 0.5532 | |||
| Total Risk Alpha | 0.3021 | |||
| Sortino Ratio | 0.1614 | |||
| Treynor Ratio | 0.5871 | |||
| Maximum Drawdown | 22.69 | |||
| Value At Risk | (5.30) | |||
| Potential Upside | 8.2 | |||
| Downside Variance | 11.87 | |||
| Semi Variance | 9.31 | |||
| Expected Short fall | (3.71) | |||
| Skewness | 0.5116 | |||
| Kurtosis | 1.02 |
Stoke Therapeutics Backtested Returns
Stoke Therapeutics appears to be very steady, given 3 months investment horizon. Stoke Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0868, which indicates the firm had a 0.0868 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Stoke Therapeutics, which you can use to evaluate the volatility of the company. Please review Stoke Therapeutics' Semi Deviation of 3.05, coefficient of variation of 675.21, and Risk Adjusted Performance of 0.1276 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Stoke Therapeutics holds a performance score of 6. The entity has a beta of 1.05, which indicates a somewhat significant risk relative to the market. Stoke Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Stoke Therapeutics is expected to follow. Please check Stoke Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Stoke Therapeutics' existing price patterns will revert.
Auto-correlation | -0.26 |
Weak reverse predictability
Stoke Therapeutics has weak reverse predictability. Overlapping area represents the amount of predictability between Stoke Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Stoke Therapeutics price movement. The serial correlation of -0.26 indicates that nearly 26.0% of current Stoke Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.26 | |
| Spearman Rank Test | 0.39 | |
| Residual Average | 0.0 | |
| Price Variance | 3.05 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Stoke Therapeutics Correlation, Stoke Therapeutics Volatility and Stoke Therapeutics Performance module to complement your research on Stoke Therapeutics. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Stoke Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.